尤瑞克林联合阿替普酶静脉溶栓对急性脑梗死患者神经功能及血液流变学的影响

Effects of intravenous thrombolysis with human urinary kallindinogenase combined with alteplase on neurological function and hemorheology in patients with acute cerebral infarction

摘要:

目的 探究尤瑞克林联合阿替普酶静脉溶栓对急性脑梗死患者神经功能及血液流变学的影响。方法 选取2018年1月—2021年12月萍乡矿业集团有限责任公司总医院收治的126例急性脑梗死患者作为研究对象。将患者分为研究组和对照组，每组63例。对照组予以阿替普酶静脉溶栓，研究组在对照组基础上联合尤瑞克林治疗，两组患者均于治疗14 d后检测血液流变学指标，评估神经功能、日常生活能力、临床疗效及药物毒性。结果 研究组治疗前后全血黏度、血浆黏度、血小板聚集率及红细胞压积的差值高于对照组（P <0.05）。研究组治疗后NIHSS评分低于对照组（P <0.05）。研究组MRS评分评估预后良好率，治疗前后ADL、BI的差值高于对照组（P <0.05）。研究组临床有效率高于对照组（P <0.05）。两组不良反应发生率比较，差异无统计学意义（P >0.05）。结论 尤瑞克林联合阿替普酶有助于改善急性脑梗死患者血液流变学状态和神经功能，提升治疗后患者日常生活能力且安全性良好。

Abstract:

Objective To explore the effects of intravenous thrombolysis with human urinary kallindinogenase and alteplase on neurological function and hemorheology in patients with acute cerebral infarction.Methods A total of 126 patients with acute cerebral infarction treated in our hospital from January 2018 to December 2021 were selected and randomly divided into the research group and the control group, with 63 cases in each group. The control group was treated with alteplase for intravenous thrombolysis, and the research group was additionally treated with human urinary kallindinogenase on the basis of alteplase. The patients in both groups were evaluated for hemorheological indexes, neurological function, activities of daily living, clinical efficacy and drug toxicity 14 days after the treatment.Results The differences of whole blood viscosity, plasma viscosity, platelet aggregation rate and hematocrit before and after the treatment were higher in the study group than in the control group (P < 0.05). NIHSS scores of the study group were lower than those of the control group after the treatment (P < 0.05). The proportion of favorable prognosis as evaluated via MRS scores and the differences of ADL and BI before and after the treatment were higher in study group than those in the control group (P < 0.05). The clinical response rate of the study group was higher than that of the control group (P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P > 0.05).Conclusions The combined treatment with human urinary kallindinogenase and alteplase improves hemorheology, the neurological function of patients, and activities of daily living with few safety concerns in patients with acute cerebral infarction.